tiprankstipranks
Trending News
More News >
Zydus Lifesciences Limited (IN:ZYDUSLIFE)
:ZYDUSLIFE
India Market
Advertisement

Zydus Lifesciences Limited (ZYDUSLIFE) AI Stock Analysis

Compare
7 Followers

Top Page

IN:ZYDUSLIFE

Zydus Lifesciences Limited

(ZYDUSLIFE)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
₹1,086.00
▲(8.40% Upside)
Zydus Lifesciences' strong financial performance is the most significant factor driving the stock score, supported by robust revenue and profit growth, and effective cash flow management. Technical analysis presents mixed signals, with short-term bearish momentum. The valuation is fair, with a reasonable P/E ratio and moderate dividend yield.

Zydus Lifesciences Limited (ZYDUSLIFE) vs. iShares MSCI India ETF (INDA)

Zydus Lifesciences Limited Business Overview & Revenue Model

Company DescriptionZydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.
How the Company Makes MoneyZydus Lifesciences generates revenue primarily through the sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs) to various markets, including India and international markets. The company has a robust product portfolio that includes branded generics and over-the-counter (OTC) products, which contribute significantly to its earnings. Revenue also comes from the development and commercialization of biosimilars, which are biologic medical products highly similar to already approved reference products. Collaborations and partnerships with other pharmaceutical companies and research institutions for the development of new drugs and therapies further enhance its revenue streams. Additionally, Zydus Lifesciences invests in research and development, which helps in introducing innovative products that meet market demands, boosting overall sales and profitability.

Zydus Lifesciences Limited Financial Statement Overview

Summary
Zydus Lifesciences demonstrates strong financial performance with impressive revenue and profit growth, a healthy balance sheet with low leverage, and robust cash flow generation. The potential risk associated with high total liabilities is mitigated by strong equity and cash flow positions.
Income Statement
85
Very Positive
Zydus Lifesciences has shown strong growth in its revenue and profitability. The gross profit margin stands at 72.7%, indicating efficient cost management. Net profit margin improved to 19.5%, reflecting enhanced profitability. Revenue growth rate is impressive at 18.9%, showing positive growth momentum. EBIT and EBITDA margins are also robust at 56.9% and 29.7%, respectively, showcasing operational efficiency.
Balance Sheet
78
Positive
The balance sheet displays healthy financial stability, with a low debt-to-equity ratio of 0.13, suggesting low leverage. The return on equity is strong at 18.9%, indicating effective use of equity. The equity ratio is also substantial at 64.4%, demonstrating a strong equity base. However, the high level of total liabilities could pose potential risks.
Cash Flow
80
Positive
Cash flow analysis shows a strong position with a free cash flow growth rate of 118.1%, indicating significant improvement in cash generation. The operating cash flow to net income ratio is 1.50, suggesting robust cash flow generation relative to net earnings. The free cash flow to net income ratio is 1.12, further validating strong cash flow management.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue236.08B232.41B195.47B172.37B151.10B144.03B
Gross Profit168.66B167.03B131.54B107.67B94.24B94.60B
EBITDA66.99B68.30B52.57B35.34B31.70B34.15B
Net Income45.72B45.26B38.59B19.60B44.87B21.34B
Balance Sheet
Total Assets0.00372.02B292.81B257.56B277.95B238.85B
Cash, Cash Equivalents and Short-Term Investments56.37B78.08B13.58B11.92B35.05B11.27B
Total Debt0.0032.13B8.04B11.95B42.21B46.08B
Total Liabilities-263.58B108.43B71.79B60.68B87.42B89.55B
Stockholders Equity263.58B239.53B198.29B175.16B170.00B129.92B
Cash Flow
Free Cash Flow0.0050.64B23.21B16.58B9.02B24.39B
Operating Cash Flow0.0067.77B32.28B26.89B21.04B32.93B
Investing Cash Flow0.00-83.72B-14.75B11.71B-10.00B-7.22B
Financing Cash Flow0.0020.14B-17.79B-44.00B-8.68B-25.49B

Zydus Lifesciences Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1001.80
Price Trends
50DMA
1005.31
Negative
100DMA
984.90
Positive
200DMA
943.95
Positive
Market Momentum
MACD
-0.01
Negative
RSI
50.84
Neutral
STOCH
74.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZYDUSLIFE, the sentiment is Positive. The current price of 1001.8 is above the 20-day moving average (MA) of 993.68, below the 50-day MA of 1005.31, and above the 200-day MA of 943.95, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.84 is Neutral, neither overbought nor oversold. The STOCH value of 74.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ZYDUSLIFE.

Zydus Lifesciences Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
₹1.05T18.440.64%14.10%9.72%
₹1.27T23.630.83%6.40%25.27%
₹893.78B23.700.61%12.40%63.16%
₹993.45B21.731.10%14.52%9.46%
₹1.22T60.490.89%7.63%15.39%
₹1.02T53.210.04%21.66%-4.92%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:ZYDUSLIFE
Zydus Lifesciences Limited
986.30
-4.20
-0.42%
IN:CIPLA
Cipla Ltd
1,580.75
43.98
2.86%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,252.60
-13.62
-1.08%
IN:LUPIN
Lupin Limited
1,956.80
-215.95
-9.94%
IN:MANKIND
Mankind Pharma Ltd.
2,444.60
-220.95
-8.29%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
3,600.00
428.67
13.52%

Zydus Lifesciences Limited Corporate Events

Zydus Lifesciences Completes Full Acquisition of Amplitude Surgical
Oct 26, 2025

Zydus Lifesciences Limited has completed the acquisition of Amplitude Surgical SA, France, through its wholly owned subsidiary, Zydus MedTech France SAS. With the acquisition of the remaining 14.4% of shares, Zydus MedTech France now fully owns Amplitude Surgical, enhancing its strategic positioning in the medical technology sector. This acquisition signifies Zydus’s commitment to expanding its footprint in the European market and strengthening its portfolio in the medical devices industry.

Zydus Lifesciences Gains Health Canada Approval for Mesalamine Suppositories
Oct 24, 2025

Zydus Lifesciences Limited has received approval from Health Canada for its generic Mesalamine suppositories, used in the treatment of mildly to moderately active ulcerative proctitis. This approval is expected to enhance Zydus’s market presence in Canada, where the product had annual sales of 4.86 million CAD, and it will be manufactured at their facility in Ahmedabad, India.

Zydus Lifesciences Issues Notice on Lost Share Certificate
Oct 4, 2025

Zydus Lifesciences Limited has announced the loss of a share certificate belonging to one of its shareholders, as published in the Financial Express. The company has issued a notice that it will issue a duplicate share certificate if no objections are received within seven days, advising the public to refrain from dealing with the lost certificate.

Zydus Lifesciences Receives Upgraded USFDA Classification for Oncology Facility
Sep 21, 2025

Zydus Lifesciences Limited has announced that it received an Establishment Inspection Report (EIR) from the USFDA for its oncology injectable facility in SEZ1, Ahmedabad. The facility’s classification has been upgraded from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI), reflecting improvements in compliance and potentially enhancing the company’s reputation and operational capabilities in the pharmaceutical industry.

Zydus and Synthon Partner for U.S. Launch of Generic Ozanimod Capsules
Sep 4, 2025

Zydus Lifesciences Ltd., through its subsidiary Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV for the generic version of Ozanimod Capsules, targeting the U.S. market. This collaboration allows Zydus to commercialize the product in the U.S., while Synthon will handle regulatory approval and manufacturing. The agreement positions Zydus to enhance its presence in the U.S. pharmaceutical market, particularly in the treatment of multiple sclerosis and ulcerative colitis, and reflects its strategic focus on expanding access to essential medicines.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 18, 2025